Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper

Canadian Journal of Clinical Pharmacology

Volumn 7, Issue 4, 2000, Pages 185-190

  Rawson, N S B ^a   West, R ^a   Appel, W C ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Conditional release; Cost effectiveness

Indexed keywords

NEW DRUG;

ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; PHARMACIST; PHYSICIAN; UNITED KINGDOM;

EID: 0034488669     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Thalidomide, practolol: What next?
2. Skin reactions to practolol
3. Skin reactions to practolol
4. Sclerosing peritonitis: An unusual reaction to a β-adrenergic-blocking drug (practolol)
5. Assessment of drug safety problems
6. Atlantic crossing and drug lag
7. Recorded release
8. Monitoring adverse reactions to drugs
9. Monitoring adverse reactions to new drugs: "Restricted release" or "monitored release"?
10. Post-marketing surveillance of adverse reactions to new medicines
11. CSM proposals for improved post-marketing surveillance
12. Prospective monitoring for adverse reactions to drugs in general practice
13. Prescription-event monitoring: Methodology and recent progress
14. Angioedema and urticaria associated with enalapril
15. Post-marketing surveillance of enalapril I: Results of prescription-event monitoring
16. Post-marketing surveillance of enalapril II: Investigation of the role of enalapril in deaths after renal failure
17. The New Zealand intensive medicines monitoring programme
18. Intensive medicines monitoring programme: Bezafibrate, gemfibrozil and simvastatin
19. Intensive medicines monitoring programme: Fluoxetine interactions
20. Intensive medicines monitoring programme: Early experience with sumatriptan
21. Prescription-event monitoring for drug safety
22. An acute adverse drug reaction alerting scheme using the Saskatchewan Health datafiles
23. Impact of pre-existing health conditions on the outcome of an adverse drug reaction alerting scheme: Gastrointestinal disorders before piroxicam and sulindac therapy
24. An acute adverse event signalling scheme using the Saskatchewan administrative health care utilization datafiles: Results for two benzodiazepines
25. Time required for approval of new drugs in Canada, Australia, Sweden, the UK and the USA in 1996-1998
26. A methodologic study of post-marketing drug evaluation using a pharmacy-based approach
27. Experience in the development of a postmarketing surveillance network: The pharmacy medication monitoring program
28. The medical dictionary for regulatory activities (MedDRA)
29. Postmarketing surveillance in Canada
30. Patient self-monitoring: A challenging approach to pharmacoepidemiology